United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - repaglinide - tablet - 1mg

United States - English - NLM (National Library of Medicine)

rising health, llc - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide 0.5 mg - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on bod

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide 0.5 mg - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: - concomitant use of gemfibrozil [see drug interactions (7)] - known hypersensitivity to repaglinide or any inactive ingredients risk summary limited available data from case reports and case series with repaglinide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body surfac

Israel - English - Ministry of Health

novo nordisk ltd., israel - repaglinide - tablets - repaglinide 1 mg - repaglinide - repaglinide - repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - repaglinide 1 mg - tablet - 1 mg - repaglinide 1 mg - repaglinide

United States - English - NLM (National Library of Medicine)

padagis us llc - repaglinide (unii: 668z8c33lu) (repaglinide - unii:668z8c33lu) - repaglinide 0.5 mg - repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitation of use: repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. repaglinide tablets are contraindicated in patients with: risk summary limited available data from case reports and case series with repaglinide tablets use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . teratogenicity was not observed in rats and rabbits administered repaglinide during organogenesis at approximately 60 and 1 times the maximum daily clinical dose, based on body surface area. no adverse developmental effects were observed in offspring of rats administered repaglinide during late gestation and lactatio

Canada - English - Health Canada

pro doc limitee - repaglinide - tablet - 1mg - repaglinide 1mg - meglitinides

Israel - English - Ministry of Health

teva pharmaceutical industries ltd, israel - repaglinide - tablets - repaglinide 1 mg - repaglinide - repaglinide - treatment of type ii diabetes.

Canada - English - Health Canada

apotex inc - repaglinide - tablet - 0.5mg - repaglinide 0.5mg - meglitinides

Canada - English - Health Canada

apotex inc - repaglinide - tablet - 1.0mg - repaglinide 1.0mg - meglitinides